Prosecution Insights
Prosecution Insights
31 pending office actions • 23 art units • 30 examiners • 0 of 31 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (3%) |
| §101 + other | 1 (3%) |
| §103 only | 11 (35%) |
| §102 only | 1 (3%) |
| §112 only | 1 (3%) |
| Double-patenting + other | 2 (6%) |
| Multi-statute (no §101) | 13 (42%) |
| No statute on record | 1 (3%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEHBE, ANNE MARIE SABRINA | 2 | 57.4% | +42.8% |
| BROWN, SETH RICHARD | 1 | 48.9% | +45.6% |
| BUI, PHUONG T | 1 | 81.2% | +23.1% |
| XIE, XIAOZHEN | 1 | 56.4% | +65.9% |
| MILLER, DALE R | 1 | 62.4% | +17.4% |
| EPSTEIN, TODD MATTHEW | 1 | 61.0% | +44.2% |
| PAGUIO FRISING, MICHELLE F | 1 | 70.8% | +40.3% |
| OLSON, ALEXANDRA NADINE | 1 | 100.0% | +0.0% |
| DIETZ, NOE ROBERT | 1 | 0.0% | +0.0% |
| GHERBI, SUZETTE JAIME J | 1 | 85.1% | +8.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030473 | ENGINEERING-DESIGN-BASED WORKFLOW FOR VALVE RECONSTRUCTION | GHERBI, SUZETTE JAIME J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | DHAR, MATASHA | 107d overdue |
| 17312248 | GENOMIC REARRANGEMENTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USING THE SAME | SISSON, BRADLEY L | 42d overdue |
| 18030467 | COMPUTATIONAL PLANNING OF SURGICAL RECONSTRUCTION | DIETZ, NOE ROBERT | 28d overdue |
| 18120301 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS | WEHBE, ANNE MARIE SABRINA | 16d overdue |
| 17928255 | ADJUVANTS FOR SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS (SARS-COV) VACCINES | CORNELIUS, CLAIRE ADRIENNE | 13d |
| 18035835 | SYSTEMS AND METHODS FOR HIGH THROUGHPUT SCREENING OF MOLECULAR INTERACTIONS | OLSON, ALEXANDRA NADINE | 23d |
| 17273684 | USE OF MESENCHYMAL STROMAL CELL EXOSOMES IN ANTENATAL THERAPY | STAVROU, CONSTANTINA E | 27d |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | PAGUIO FRISING, MICHELLE F | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18120301 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS | WEHBE, ANNE MARIE SABRINA | 16d overdue |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | PAGUIO FRISING, MICHELLE F | 34d |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | EPSTEIN, TODD MATTHEW | 82d |
| 19003564 | SOFT BRACES TO PREVENT INJURY TO A JOINT OR BODY SEGMENT | BROWN, SETH RICHARD | — |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | — |
| 18577206 | SYSTEMS AND METHODS FOR DELIVERY BASED ON SUPRAMOLECULAR NANOSTRUCTURES | XIE, XIAOZHEN | — |
| 18396181 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MILLER, DALE R | — |
| 16639474 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1699 | 2 |
| 1634 | 2 |
| 1633 | 2 |
| 1691 | 2 |
| 3786 | 1 |
| 1663 | 1 |
| 4100 | 1 |
| 1651 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19003564 | SOFT BRACES TO PREVENT INJURY TO A JOINT OR BODY SEGMENT | BROWN, SETH RICHARD | 3786 | §103 | Final Rejection | — | Pending | Dec 27, 2024 |
| 18579325 | EXTRACHROMOSOMAL CIRCULAR DNA AS AN IMMUNOSTIMULANT AND BIOMARKER FOR DISEASE | BUI, PHUONG T | 1663 | §102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18577206 | SYSTEMS AND METHODS FOR DELIVERY BASED ON SUPRAMOLECULAR NANOSTRUCTURES | XIE, XIAOZHEN | — | §102§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18396181 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MILLER, DALE R | 4100 | §102§103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18282215 | ENGINEERED BOTULINUM NEUROTOXIN A PROTEASE DOMAIN WITH IMPROVED EFFICACY | EPSTEIN, TODD MATTHEW | 1699 | §102 | Non-Final OA | 82d | Pending | Sep 14, 2023 |
| 18268477 | IMPROVED RECEPTOR-BINDING DOMAIN OF BOTULINUM NEUROTOXIN A AND USES THEREOF | PAGUIO FRISING, MICHELLE F | 1651 | §102§103 | Non-Final OA | 34d | Pending | Jun 20, 2023 |
| 18035835 | SYSTEMS AND METHODS FOR HIGH THROUGHPUT SCREENING OF MOLECULAR INTERACTIONS | OLSON, ALEXANDRA NADINE | 1684 | §102§103Other | Non-Final OA | 23d | Pending | May 08, 2023 |
| 18030467 | COMPUTATIONAL PLANNING OF SURGICAL RECONSTRUCTION | DIETZ, NOE ROBERT | 3791 | §103 | Final Rejection | 28d overdue | Pending | Apr 05, 2023 |
| 18030473 | ENGINEERING-DESIGN-BASED WORKFLOW FOR VALVE RECONSTRUCTION | GHERBI, SUZETTE JAIME J | 3774 | §103 | Non-Final OA | — | Pending | Apr 05, 2023 |
| 18120301 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112Other | Non-Final OA | 16d overdue | Pending | Mar 10, 2023 |
| 18168131 | FORCE-CONTROLLED NANOSWITCH ASSAYS FOR SINGLE-MOLECULE DETECTION IN COMPLEX BIOLOGICAL FLUIDS | HORLICK, KENNETH R | — | §112DP | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18015209 | TARGETED DRUG DELIVERY TO SITES OF INTRAVASCULAR OCCLUSION | UNDERDAHL, THANE E | 1699 | §103 | Final Rejection | 46d | Pending | Jan 09, 2023 |
| 18014901 | GUIDING BLOOD PRODUCT ADMINISTRATION TO MITIGATE BLEEDING RISK | FRITCHMAN, REBECCA M | 1758 | §101 | Non-Final OA | — | Pending | Jan 06, 2023 |
| 17928255 | ADJUVANTS FOR SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS (SARS-COV) VACCINES | CORNELIUS, CLAIRE ADRIENNE | 1672 | §102§103§112 | Non-Final OA | 13d | Pending | Nov 28, 2022 |
| 17794861 | DEVICE FOR VISUALIZATION OF VALVE DURING SURGERY | FREHE, WILLIAM R | 3783 | §103§112 | Final Rejection | — | Pending | Jul 22, 2022 |
| 17855719 | TISSUE FASTENING | SCHERBEL, TODD J | 3771 | §103 | Non-Final OA | 33d | Pending | Jun 30, 2022 |
| 17777659 | STIMULI THAT HYPERACTIVATE RESIDENT DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY | CHATTIN, AMY MARIE | 1643 | §103 | Final Rejection | 91d overdue | Pending | May 18, 2022 |
| 17769536 | METHODS FOR MULTI-FOCAL IMAGING FOR MOLECULAR PROFILING | CROW, ROBERT THOMAS | 1600 | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2022 |
| 17637305 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | PETRASH, HILARY ANN | 1644 | §102§103§112DP | Final Rejection | — | Pending | Feb 22, 2022 |
| 17635409 | LARGE SCALE PRODUCTION OF EXOSOME MIMETICS AND USES THEREOF | MEJIAS, SAMANTHA LEE | 1618 | §103 | Final Rejection | 14d | Pending | Feb 15, 2022 |
| 17486855 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE | FOX, ALLISON M | 1633 | §101§112 | Non-Final OA | — | Pending | Sep 27, 2021 |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 53d overdue | Pending | Jul 13, 2021 |
| 17371017 | MYBPC3 POLYPEPTIDES AND USES THEREOF | DHAR, MATASHA | 1632 | §103§112 | Final Rejection | 107d overdue | Pending | Jul 08, 2021 |
| 17312248 | GENOMIC REARRANGEMENTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USING THE SAME | SISSON, BRADLEY L | 1682 | §103§112 | Non-Final OA | 42d overdue | Pending | Jun 09, 2021 |
| 17275266 | NANOPARTICLE FORMULATIONS AND METHODS OF THEIR USE | MACH, ANDRE | 1615 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17273684 | USE OF MESENCHYMAL STROMAL CELL EXOSOMES IN ANTENATAL THERAPY | STAVROU, CONSTANTINA E | 1632 | §102§103 | Non-Final OA | 27d | Pending | Mar 04, 2021 |
| 17053752 | MESENCHYMAL STROMAL CELL EXOSOME-TREATED MONOCYTES AND USES THEREOF | WESTON, ALYSSA G | 1633 | §102§103 | Non-Final OA | — | Pending | Nov 06, 2020 |
| 17045412 | COMPOSITIONS AND METHODS FOR SOMATIC CELL REPROGRAMMING AND MODULATING IMPRINTING | BERTOGLIO, VALARIE E | 1632 | Other | Final Rejection | 52d overdue | Pending | Oct 05, 2020 |
| 16979084 | COMPOSITIONS AND METHODS FOR MUTATIONS ASSOCIATED WITH SUDDEN UNEXPECTED DEATH IN PEDIATRICS | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 128d overdue | Pending | Sep 08, 2020 |
| 16639474 | PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF | WEHBE, ANNE MARIE SABRINA | 1634 | §112 | Non-Final OA | — | Pending | Feb 14, 2020 |
| 16628162 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | BEANE, RANDALL L | 1654 | §103 | Final Rejection | — | Pending | Jan 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial